Atea Pharmaceuticals (AVIR) Non-Current Assets (2019 - 2026)

Atea Pharmaceuticals' Non-Current Assets history runs 8 years deep, the most recent figure standing at $3.9 million for Q1 2026.

• On a quarterly basis, Non-Current Assets fell 38.0% year-over-year to $3.9 million in Q1 2026; TTM through Mar 2026 was $20.9 million, a 25.83% increase from a year earlier, with the FY2025 full-year figure at $4.2 million, up 82.75% from the prior year.
• Non-Current Assets declined to $3.9 million in Q1 2026 per AVIR's latest filing, from $4.2 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $6.8 million in Q3 2025 and bottomed at $2.3 million in Q4 2024.
• The 5-year median for Non-Current Assets is $4.6 million (2022), against an average of $4.8 million.
• Across the five-year window, Non-Current Assets jumped 1083.23% in 2022 and tumbled 48.75% in 2024, its largest moves.
• Year by year, Non-Current Assets stood at $5.8 million in 2022, then fell by 22.0% to $4.5 million in 2023, then tumbled by 48.75% to $2.3 million in 2024, then soared by 82.75% to $4.2 million in 2025, then declined by 8.23% to $3.9 million in 2026.
• Per Business Quant, the three latest AVIR Non-Current Assets figures stand at $3.9 million (Q1 2026), $4.2 million (Q4 2025), and $6.8 million (Q3 2025).